Table 1. Comparative effects of selective enzyme inhibition on ¹²⁵I-Ang-(1–12) metabolism in medium of cultured neonatal wky and shr cardiac myocytes.

Peptides	No RAS Inhibitors	+All RAS Inhibitors	Minus Lisinopril	Minus SCH39370	Minus MLN-4760	Minus Chymostatin
Wistar Kyoto Rats
Ang-(1–12)*	26±3a	90±2	41±7b	58±4b	92±2	87±3
Ang I	14±1a	4±1	18±5b	7±2	3±1	5±2
Ang II	37±5a	3±1	33±4b	6±3	2±1	3±1
Ang-(1–5)	3±1	1±1	2±1	2±1	1±1	1±1
Ang-(1–7)	7±2	1±1	4±1	7±1b	1±1	1±1
Ang-(1–4) & smaller peptides	13±3a	1±1	2±1	20±2b	1±1	3±1
Spontaneous Hypertensive Rats
Ang-(1–12)*	8±2a,c	71±2c	27±4b	38±4b,c	84±6	51±5b,c
Ang I	10±3	4±1	18±2b	8±1	5±2	20±3b,c
Ang II	29±5a	14±2c	42±4b	7±2	6±3	21±4c
Ang-(1–5)	6±1	1±1	3±1	1±1	2±1	2±1
Ang-(1–7)	10±2	4±2	3±1	13±2b	2±1	2±1
Ang-(1–4) & smaller peptides	37±5a,c	6±2	7±3	33±7b	3±1	4±1

Values are expressed as % (Mean ± SE) of Ang-(1–12) unmetabolized* and Ang peptides (%) generated from ¹²⁵I-Ang-(1–12) in the cultured medium incubated for 60 min at 37°C to WKY or SHR myocytes with or without the presence of RAS inhibitors. No inhibitors group: Only aminopeptidases inhibitors (amastatin & bestatin) and carboxypeptidases inhibitor (benzyl succinate); All inhibitors group: Aminopeptidases and carboxypeptidases inhibitors + RAS inhibitors (lisinopril, SCH39370, MLN-4760 & chymostatin); Minus RAS inhibitor groups: One of the RAS inhibitor (lisinopril/SCH39370/MLN-4760/chymostatin) omitted at a time from all inhibitors group. All values are expressed as (%) and are the average of three or more independent assays.

*Percent of ¹²⁵IAng-(1–12) parent control remained un-metabolized in the medium exposed to WKY or SHR myocytes for 60 min at 37°C.

^aSignificantly different (P<0.05) in No RAS inhibitors group vs. corresponding WKY or SHR group of +All RAS inhibitors.

^bSignificantly different (P<0.05) vs. corresponding group of +All RAS inhibitors.

^cSignificantly different (P<0.05) vs. corresponding WKY.